33 results on '"Behrens, Frank"'
Search Results
2. Proceedings of the Collaborative Research Network Meeting at the GRAPPA 2022 Annual Meeting.
- Author
-
Ng BCK, Jadon D, Behrens F, de Wit M, FitzGerald O, Gladman DD, Mease PJ, O'Sullivan D, Pennington SR, Schett G, Chandran V, and de Vlam K
- Subjects
- Humans, Biomarkers, Social Group, Arthritis, Psoriatic, Psoriasis, Rheumatology, Dermatology
- Abstract
At the Group for Research and Assessment of Psoriasis and Psoriatic Arthritis (GRAPPA) 2022 annual meeting, the Collaborative Research Network (CRN) met to present updates on several projects. These included the GRAPPA-Industry biomarker projects, Axial Psoriatic Arthritis Molecular and Clinical Characterisation Study, Axial Involvement in Psoriatic Arthritis Cohort (AXIS) study, and the Health Initiatives in Psoriasis and Psoriatic Arthritis Consortium European States (HIPPOCRATES). The meeting concluded with a discussion on pathways to further academia-industry collaboration., (Copyright © 2023 by the Journal of Rheumatology.)
- Published
- 2023
- Full Text
- View/download PDF
3. Association between biological immunotherapy for psoriasis and time to incident inflammatory arthritis: limitations and opportunities.
- Author
-
Koehm M and Behrens F
- Subjects
- Humans, Prospective Studies, Retrospective Studies, Immunotherapy, Interleukin-23, Arthritis, Psoriatic drug therapy, Arthritis, Psoriatic epidemiology, Psoriasis complications, Psoriasis drug therapy, Psoriasis epidemiology
- Abstract
Psoriatic arthritis (PsA) is a chronic inflammatory immune-mediated disease that affects approximately 30% of psoriasis patients. In most cases, skin disease clearly precedes the musculoskeletal disease. Some studies suggest that targeted treatment may intercept the disease course and prevent psoriasis patients from developing PsA. A recent population-based retrospective analysis in 15 501 psoriasis patients evaluated the association between different biological treatment strategies and time to incident inflammatory arthritis based on data in a US electronic health records database. A cumulative incidence of 2.6 PsA cases per 100 person-years was determined. The multivariable regression analysis revealed a significantly lower risk of developing inflammatory arthritis in patients who had been prescribed interleukin (IL)-12/23 or IL-23 inhibitors compared with tumour necrosis factor (TNF) inhibitor-treated patients, whereas there was no significant difference in risk for patients prescribed inhibitors of IL-17 versus TNF. Although the analysis was based on a large set of clinical data and the findings were rigorously evaluated, there are some limitations in interpretation due to the study design. Prospective clinical trials are missing, and retrospective data analyses from clinical trials or population-based studies show conflicting results. Overall, the recent data on prevention of PsA in patients with psoriasis support the high need to characterise biomarkers of increased risk and perform prospective clinical trials to give a clear guidance on possibilities for disease interception in psoriatic disease., Competing Interests: Competing interests: MK received consulting fees or honoraria from Amgen, Janssen-Cilag, Lilly, Novartis and UCB, and received travel support from UCB, AbbVie and Janssen-Cilag. FB received consulting fees or honoraria from Abbvie, Acelyrin, Amgen, Janssen Cilag, Lily, Novartis, Pfizer and UCB, and meeting or travel support from Abbvie and UCB., (© Author(s) (or their employer(s)) 2023. Re-use permitted under CC BY-NC. No commercial re-use. See rights and permissions. Published by BMJ.)
- Published
- 2023
- Full Text
- View/download PDF
4. Comparison of patients with axial PsA and patients with axSpA and concomitant psoriasis: an analysis of the German register RABBIT-SpA.
- Author
-
Regierer AC, Weiß A, Proft F, Baraliakos X, Behrens F, Poddubnyy D, Schett G, Lorenz HM, Worsch M, and Strangfeld A
- Subjects
- Female, Humans, Prospective Studies, Longitudinal Studies, Pain, Inflammation, Arthritis, Psoriatic complications, Spondylitis, Ankylosing drug therapy, Psoriasis complications, Axial Spondyloarthritis
- Abstract
Background: Psoriatic arthritis (PsA) and axial spondyloarthritis (axSpA) show certain overlaps: A subset of patients with PsA can develop axial involvement (axial PsA, axPsA), while a subset of patients with axSpA presents with psoriasis (axSpA+pso). Treatment strategy for axPsA is mostly based on axSpA evidence., Objectives: To compare demographic and disease-specific parameters of axPsA and axSpA+pso., Methods: RABBIT-SpA is a prospective longitudinal cohort study. AxPsA was defined based on (1) clinical judgement by rheumatologists; (2) imaging (sacroiliitis according to modified New York criteria in radiographs or signs of active inflammation in MRI or syndesmophytes/ankylosis in radiographs or signs of active inflammation in spine MRI). axSpA was stratified into axSpA+pso and axSpA without pso., Results: Psoriasis was documented in 181/1428 axSpA patients (13%). Of 1395 PsA patients, 359 (26%) showed axial involvement. 297 patients (21%) fulfilled the clinical definition and 196 (14%) the imaging definition of axial manifestation of PsA. AxSpA+pso differed from axPsA regardless whether clinical or imaging definition was used. axPsA patients were older, more often female and less often HLA-B27+. Peripheral manifestations were more often present in axPsA than in axSpA+pso, whereas uveitis and inflammatory bowel disease were more common in axSpA+pso. Burden of disease (patient global, pain, physician global) was similar among axPsA and axSpA+pso patients., Conclusions: AxPsA differs from axSpA+pso in its clinical manifestations, irrespective of whether axPsA is defined clinically or by imaging. These findings support the hypothesis that axSpA and PsA with axial involvement are distinct entities, so extrapolation of treatment data from randomised controlled trials in axSpA should be performed with caution., Competing Interests: Competing interests: None declared., (© Author(s) (or their employer(s)) 2023. Re-use permitted under CC BY-NC. No commercial re-use. See rights and permissions. Published by BMJ.)
- Published
- 2023
- Full Text
- View/download PDF
5. Fluorescence-optical imaging as a promising easy-to-use imaging biomarker to increase early psoriatic arthritis detection in patients with psoriasis: a cross-sectional cohort study with follow-up.
- Author
-
Koehm M, Ohrndorf S, Foldenauer AC, Rossmanith T, Backhaus M, Werner SG, Burmester GR, Wassenberg S, Koehler B, Burkhardt H, and Behrens F
- Subjects
- Adult, Humans, Cross-Sectional Studies, Follow-Up Studies, Optical Imaging methods, Prospective Studies, Arthritis, Psoriatic diagnosis, Arthritis, Psoriatic diagnostic imaging, Psoriasis complications, Psoriasis diagnosis
- Abstract
Objectives: To evaluate the ability of fluorescence-optical imaging (FOI) to detect preclinical musculoskeletal inflammatory signs in patients with skin psoriasis at risk of developing psoriatic arthritis (PsA)., Methods: This investigator-initiated prospective exploratory study evaluated adult patients with psoriasis with musculoskeletal complaints and/or nail psoriasis within the last 6 months. Patients underwent a comprehensive rheumatological clinical examination (CE) along with musculoskeletal ultrasound (MSUS) and FOI of both hands at a single visit. Patients with CE-/MSUS-/FOI+ findings had MRI performed on the symptomatic or dominant hand within 7 days. If MRI was negative, the patients were followed over 2 years for the onset of clinically manifest PsA., Results: A total of 389 patients were referred from dermatology centres and evaluated at 14 rheumatology sites in Germany. Seventy-seven (20%) patients with CE-/US-/FOI- were considered to have psoriasis only. PsA was diagnosed in 140/389 patients (36%) based on CE alone and in another 55 patients (14%) by additional MSUS; overall, 50% of the patient cohort was diagnosed with PsA. One hundred sixteen patients (30%) were FOI+ (CE-) of which 40 (37%) were FOI+/MRI+. In the 2-year follow-up of the FOI+/CE- patients, clinical PsA was confirmed in another 12%., Conclusion: FOI is a promising method for the detection of signs of musculoskeletal inflammation in hands that may serve as an early imaging biomarker for transitions from psoriasis to PsA. This imaging technique has the potential to detect PsA in at-risk patients with psoriasis, reduce time to PsA diagnosis and improve patient outcomes., Competing Interests: Competing interests: MK, ACF, TR, HB and FB are supported by Fraunhofer ITMP, the sponsor of this study. MK received research grants from Bionorica, BMS, Iron4u, LEO, Janssen-Cilag, Novartis and Pfizer and speaker’s fees, consulting fees and/or conference support from AbbVie, Janssen-Cilag, Lilly, Novartis, Pfizer and UCB. SGW participated in project planning boards with the owner of Xiralite GmbH and Pfizer as sponsor, but did not receive personal compensation. GRB is on the editorial board of RMD Open. SW received speaker’s fees and/or conference support from AbbVie, Gilead, Lilly, MSD, Mylan, Pfizer, Rheumaklinik Sendenhorst, Rheumatologische Fortbildungsakademie (Berlin), Rheumazentrum Rhein Ruhr, Sanofi, streamedup and UCB, and participated on data safety monitoring or advisory boards for AbbVie, BMS, Galapagos, Gilead, Lilly and UCB. BK received funding from Fraunhofer Institute for this study, speaker’s fees, conference support and/or advisory board fees from AbbVie, Boehringer Ingelheim, Celegen, Janssen, Lilly, Novartis, Pfizer. HB received research support from the Fraunhofer Cluster of Excellence for Immune-mediated Diseases (a non-profit organisation) and speaker’s fees, consulting fees and/or conference support from Janssen-Cilag and Roche. FB received grants/research support from Bionorica, BMS, Iron4u, Janssen-Cilag, LEO, Novartis and Pfizer, speaker’s fees, consulting fees and/or conference support from AbbVie, Affibody, Amgen, Boehringer-Ingelheim, Galapagos, GSK, Janssen-Cilag, Lilly, MoonLake, MSD, Novartis, Pfizer, Sandoz, Sanofi and UCB and serves on data safety monitoring or advisory boards for AbbVie, Amgen, Boehringer, Galapagos, Janssen-Cilag, Lilly, Novartis, Pfizer, Roche, Sandoz, Sanofi and UCB., (© Author(s) (or their employer(s)) 2022. Re-use permitted under CC BY-NC. No commercial re-use. See rights and permissions. Published by BMJ.)
- Published
- 2022
- Full Text
- View/download PDF
6. [Treatment of psoriasis with secukinumab : Practical guidance].
- Author
-
Körber A, Augustin M, Behrens F, Gerdes S, von Kiedrowski R, Schäkel K, Sticherling M, Wilsmann-Theis D, Wohlrab J, and Simon JC
- Subjects
- Antibodies, Monoclonal therapeutic use, Antibodies, Monoclonal, Humanized, Female, Humans, Pregnancy, Severity of Illness Index, Treatment Outcome, Psoriasis diagnosis, Psoriasis drug therapy, Quality of Life
- Abstract
Background: Moderate to severe plaque psoriasis can be treated effectively with immunomodulating biologicals such as the interleukin-17A inhibitor secukinumab. In practice, however, questions often arise as to how to proceed in special situations, such as infections, comorbidity, pregnancy, or surgery., Objectives: To address frequent questions about the treatment of plaque psoriasis with secukinumab in a consensus document of German psoriasis experts that supplements current guidelines., Methods: In a virtual expert meeting in May 2020, practical aspects of the treatment of psoriasis were discussed based on the experience of the participants and on current literature. The results of this discussion were summarized in the present consensus document., Results: This article provides practical guidance on case history, documentation of previous therapies, severity of psoriasis, and comorbidities before starting therapy with secukinumab. For patients treated with secukinumab, the course of action in case of vaccinations, chronic or acute infections, surgical interventions, special manifestations of psoriasis, and comorbidities including history of cancer and autoimmune disorders is discussed. Questions regarding family planning and health policy regulations are also addressed., Discussion: The recommendations for the treatment of psoriasis with secukinumab summarized in this consensus document may contribute to achieve optimal therapy for patients and to improve their quality of life., (© 2021. The Author(s).)
- Published
- 2021
- Full Text
- View/download PDF
7. Genetic Analysis of MPO Variants in Four Psoriasis Subtypes in Patients from Germany.
- Author
-
Haskamp S, Horowitz JS, Oji V, Philipp S, Sticherling M, Schäkel K, Schuhmann S, Prinz JC, Burkhardt H, Behrens F, Böhm B, Köhm M, Rech J, Simon D, Schett G, Morrison K, Gerdes S, Assmann G, Nimeh A, Schuster V, Jacobi A, Weyergraf A, Reis A, Uebe S, Wilsmann-Theis D, Mößner R, and Hüffmeier U
- Subjects
- Arthritis, Psoriatic diagnosis, Arthritis, Psoriatic epidemiology, Genetic Testing, Germany epidemiology, Humans, Polymorphism, Single Nucleotide, Psoriasis diagnosis, Psoriasis epidemiology, Severity of Illness Index, Arthritis, Psoriatic genetics, Genetic Predisposition to Disease, Peroxidase genetics, Psoriasis genetics
- Published
- 2021
- Full Text
- View/download PDF
8. A 12-point recommendation framework to support advancement of the multidisciplinary care of psoriatic arthritis: A call to action.
- Author
-
Gratacós J, Behrens F, Coates LC, Lubrano E, Thaçi D, Bundy C, de la Torre-Aboki J, Luelmo J, Voorneveld H, and Richette P
- Subjects
- Europe, France, Humans, Italy, Netherlands, Spain, United Kingdom, Arthritis, Psoriatic diagnosis, Arthritis, Psoriatic epidemiology, Arthritis, Psoriatic therapy, Psoriasis
- Abstract
Objective: Making a differential diagnosis of psoriatic arthritis (PsA) is not straightforward. This is partly because of its heterogeneous presentation and partly because many patients with PsA are initially diagnosed with psoriasis and treated in primary care or by dermatologists, with referral to rheumatologists being delayed. Once diagnosed, optimal disease control requires frequent specialist monitoring, adjustment or switching of therapies, and management of comorbidities and concomitant diseases, as well as attention to patients' overall well-being. Given the breadth of expertise that diagnosis and management of PsA requires, we sought to define a collaborative, structured framework that supports the optimisation of multidisciplinary care for patients with PsA in Europe., Methods: An expert panel comprising four rheumatologists, three dermatologists, two specialist nurses and one psychologist-from Spain, the United Kingdom, The Netherlands, Germany, France and Italy-met face-to-face to take part in a modified Delphi exercise., Results: The result of this exercise is a set of recommendations that are based on combining published evidence with the panel's extensive clinical experience. Recommendations can be implemented in a number of ways, but the central call-to-action of this framework is the need for improved collaboration between dermatologists (or primary care physicians) and rheumatologists. This could occur in a variety of different formats: standard referral pathways, multidisciplinary physician meetings to discuss patient cases, or 'one stop', combined clinics., Conclusion: We anticipate that when the majority of patients with PsA receive regular multidisciplinary care, improved patient outcomes will follow, although robust research is needed to explore this assumption., (Copyright © 2021 The Authors. Published by Elsevier Masson SAS.. All rights reserved.)
- Published
- 2021
- Full Text
- View/download PDF
9. Rare Loss-of-Function Mutation in SERPINA3 in Generalized Pustular Psoriasis.
- Author
-
Frey S, Sticht H, Wilsmann-Theis D, Gerschütz A, Wolf K, Löhr S, Haskamp S, Frey B, Hahn M, Ekici AB, Uebe S, Thiel C, Reis A, Burkhardt H, Behrens F, Köhm M, Rech J, Schett G, Assmann G, Kingo K, Kõks S, Mössner R, Prinz JC, Oji V, Schulz P, Muñoz LE, Kremer AE, Wenzel J, and Hüffmeier U
- Subjects
- Adult, Aged, Alleles, Exanthema, Female, Genetic Predisposition to Disease, HaCaT Cells, Heterozygote, Humans, Male, Middle Aged, Mutation, Mutation, Missense, Psoriasis genetics, Serpins genetics, Skin Diseases, Vesiculobullous genetics
- Published
- 2020
- Full Text
- View/download PDF
10. Analyses of association of psoriatic arthritis and psoriasis vulgaris with functional NCF1 variants.
- Author
-
Löhr S, Ekici AB, Uebe S, Büttner C, Köhm M, Behrens F, Böhm B, Sticherling M, Schett G, Simon D, Mössner R, Nimeh A, Oji V, Assmann G, Rech J, Holmdahl R, Burkhardt H, Reis A, and Hüffmeier U
- Subjects
- Adult, Case-Control Studies, Female, Humans, Male, Middle Aged, Arthritis, Psoriatic genetics, Genetic Variation, NADPH Oxidases genetics, Psoriasis genetics
- Published
- 2019
- Full Text
- View/download PDF
11. Simultaneous Response in Several Domains in Patients with Psoriatic Disease Treated with Etanercept as Monotherapy or in Combination with Conventional Synthetic Disease-modifying Antirheumatic Drugs.
- Author
-
Behrens F, Meier L, Prinz JC, Jobst J, Lippe R, Löschmann PA, and Lorenz HM
- Subjects
- Adult, Drug Therapy, Combination, Female, Humans, Male, Middle Aged, Prospective Studies, Quality of Life, Treatment Outcome, Antirheumatic Agents therapeutic use, Arthritis, Psoriatic drug therapy, Etanercept therapeutic use, Methotrexate therapeutic use, Psoriasis drug therapy
- Abstract
Objective: To evaluate patients with psoriatic arthritis (PsA) receiving etanercept (ETN) monotherapy or ETN plus conventional synthetic disease-modifying antirheumatic drugs (csDMARD) to determine the proportion achieving a clinically meaningful response in arthritis, psoriasis, and quality of life simultaneously., Methods: A prospective, multicenter, 52-week observational study in patients with active PsA evaluated treatment with ETN in clinical practice (ClinicalTrials.gov: NCT00293722). This analysis assessed simultaneous achievement of 3 treatment targets: low disease activity (LDA) based on 28-joint count Disease Activity Score (DAS28); body surface area (BSA) involvement ≤ 3%; and a score > 45 on the Medical Outcomes Study Short Form-12 (SF-12) physical component summary., Results: Of 579 patients, 380 received ETN monotherapy and 199 received combination ETN plus csDMARD. At 52 weeks, data for all 3 disease domains were available for 251 patients receiving monotherapy and 151 receiving combination therapy. In the monotherapy and combination therapy groups, 61 (24.3%) and 37 (24.5%) patients, respectively, achieved all 3 treatment targets simultaneously. A significantly greater proportion of patients receiving monotherapy versus combination therapy achieved SF-12 > 45 (43.0% vs 31.8%; p < 0.05) and DAS28 LDA (72.5% vs 62.3%; p < 0.05). Conversely, BSA ≤ 3% was reached by a significantly greater proportion receiving combination therapy (75.5% vs 56.6%; p < 0.001). However, baseline BSA involvement was higher for the monotherapy group., Conclusion: While nearly half the patients achieved arthritis and psoriasis treatment targets simultaneously and one-fourth reached all 3 treatment targets, combining ETN and csDMARD did not substantially improve clinical response compared with ETN monotherapy in this real-world PsA patient population.
- Published
- 2018
- Full Text
- View/download PDF
12. Dense genotyping of immune-related susceptibility loci reveals new insights into the genetics of psoriatic arthritis.
- Author
-
Bowes J, Budu-Aggrey A, Huffmeier U, Uebe S, Steel K, Hebert HL, Wallace C, Massey J, Bruce IN, Bluett J, Feletar M, Morgan AW, Marzo-Ortega H, Donohoe G, Morris DW, Helliwell P, Ryan AW, Kane D, Warren RB, Korendowych E, Alenius GM, Giardina E, Packham J, McManus R, FitzGerald O, McHugh N, Brown MA, Ho P, Behrens F, Burkhardt H, Reis A, and Barton A
- Subjects
- Adult, Aged, Aged, 80 and over, Alleles, Arthritis, Psoriatic immunology, Arthritis, Psoriatic metabolism, Arthritis, Psoriatic pathology, CD4-Positive T-Lymphocytes immunology, CD4-Positive T-Lymphocytes metabolism, CD4-Positive T-Lymphocytes pathology, CD8-Positive T-Lymphocytes immunology, CD8-Positive T-Lymphocytes pathology, Case-Control Studies, Chromatin chemistry, Chromatin immunology, Chromosomes, Human, Pair 5, Female, Genetic Predisposition to Disease, Genotype, Genotyping Techniques, Histocompatibility Antigens Class I immunology, Humans, Immunologic Memory, Male, Microarray Analysis, Middle Aged, Polymorphism, Single Nucleotide, Psoriasis immunology, Psoriasis metabolism, Psoriasis pathology, Receptors, Interleukin immunology, Arthritis, Psoriatic genetics, CD8-Positive T-Lymphocytes metabolism, Histocompatibility Antigens Class I genetics, Psoriasis genetics, Quantitative Trait Loci immunology, Receptors, Interleukin genetics
- Abstract
Psoriatic arthritis (PsA) is a chronic inflammatory arthritis associated with psoriasis and, despite the larger estimated heritability for PsA, the majority of genetic susceptibility loci identified to date are shared with psoriasis. Here, we present results from a case-control association study on 1,962 PsA patients and 8,923 controls using the Immunochip genotyping array. We identify eight loci passing genome-wide significance, secondary independent effects at three loci and a distinct PsA-specific variant at the IL23R locus. We report two novel loci and evidence of a novel PsA-specific association at chromosome 5q31. Imputation of classical HLA alleles, amino acids and SNPs across the MHC region highlights three independent associations to class I genes. Finally, we find an enrichment of associated variants to markers of open chromatin in CD8(+) memory primary T cells. This study identifies key insights into the genetics of PsA that could begin to explain fundamental differences between psoriasis and PsA.
- Published
- 2015
- Full Text
- View/download PDF
13. Common variants at TRAF3IP2 are associated with susceptibility to psoriatic arthritis and psoriasis.
- Author
-
Hüffmeier U, Uebe S, Ekici AB, Bowes J, Giardina E, Korendowych E, Juneblad K, Apel M, McManus R, Ho P, Bruce IN, Ryan AW, Behrens F, Lascorz J, Böhm B, Traupe H, Lohmann J, Gieger C, Wichmann HE, Herold C, Steffens M, Klareskog L, Wienker TF, Fitzgerald O, Alenius GM, McHugh NJ, Novelli G, Burkhardt H, Barton A, and Reis A
- Subjects
- Adaptor Proteins, Signal Transducing, DNA Replication, Diseases in Twins genetics, Genotype, Humans, Interleukins genetics, Twins, Monozygotic, Arthritis, Psoriatic genetics, Chromosomes, Human, Pair 6 genetics, Genetic Predisposition to Disease, Polymorphism, Single Nucleotide, Psoriasis genetics, Tumor Necrosis Factor Receptor-Associated Peptides and Proteins genetics
- Abstract
Psoriatic arthritis (PsA) is an inflammatory joint disease that is distinct from other chronic arthritides and which is frequently accompanied by psoriasis vulgaris (PsV) and seronegativity for rheumatoid factor. We conducted a genome-wide association study in 609 German individuals with PsA (cases) and 990 controls with replication in 6 European cohorts including a total of 5,488 individuals. We replicated PsA associations at HLA-C and IL12B and identified a new association at TRAF3IP2 (rs13190932, P = 8.56 × 10⁻¹⁷). TRAF3IP2 was also associated with PsV in a German cohort including 2,040 individuals (rs13190932, P = 1.95 × 10⁻³). Sequencing of the exons of TRAF3IP2 identified a coding variant (p.Asp10Asn, rs33980500) as the most significantly associated SNP (P = 1.13 × 10⁻²⁰, odds ratio = 1.95). Functional assays showed reduced binding of this TRAF3IP2 variant to TRAF6, suggesting altered modulation of immunoregulatory signals through altered TRAF interactions as a new and shared pathway for PsA and PsV.
- Published
- 2010
- Full Text
- View/download PDF
14. Clinical and genetic registries in psoriatic disease.
- Author
-
Gladman DD, Rahman P, Krueger GG, Mease PJ, Qureshi AA, Dutz JP, Lindqvist U, Carneiro S, Helliwell PS, Ujfalussy I, Gottlieb AB, Behrens F, and Ståhle M
- Subjects
- Genetic Predisposition to Disease, Humans, Clinical Trials as Topic, Psoriasis genetics, Registries
- Abstract
Clinical and genetic registries are an important tool in studying psoriasis and psoriatic arthritis (PsA). They assist in delineating disease features and are crucial in defining phenotype and identifying genetic and other markers of disease expression. At the 2007 Annual Meeting of the Group for Research and Assessment of Psoriasis and Psoriatic Arthritis (GRAPPA), members of the clinical registries and genetics committees described several ongoing registries, including their construction, protocols, and some results from their analyses. In breakout groups, members discussed data issues, including identification of core datasets, ownership, and how to share data; and ethical issues and possible sources of funding for registries. Proceedings of these meetings are summarized.
- Published
- 2008
15. Leflunomide improves psoriasis in patients with psoriatic arthritis: an in-depth analysis of data from the TOPAS study.
- Author
-
Nash P, Thaçi D, Behrens F, Falk F, and Kaltwasser JP
- Subjects
- Adjuvants, Immunologic administration & dosage, Adjuvants, Immunologic therapeutic use, Administration, Oral, Adult, Aged, Anti-Inflammatory Agents, Non-Steroidal administration & dosage, Double-Blind Method, Female, Humans, Immunosuppressive Agents administration & dosage, Isoxazoles administration & dosage, Leflunomide, Male, Middle Aged, Psoriasis pathology, Quality of Life, Skin pathology, Anti-Inflammatory Agents, Non-Steroidal therapeutic use, Arthritis, Psoriatic drug therapy, Immunosuppressive Agents therapeutic use, Isoxazoles therapeutic use, Psoriasis drug therapy
- Abstract
Background: Leflunomide has shown promise in the treatment of psoriasis., Objective: To provide an in-depth analysis of the effect of leflunomide on psoriasis in patients with psoriatic arthritis (PsA)., Methods: 190 patients with plaque psoriasis (at least 3% skin involvement) and active PsA were randomized to double-blind treatment with leflunomide (100 mg/day loading dose for 3 days followed by 20 mg/day orally) or placebo for 24 weeks., Results: As previously reported, leflunomide resulted in a significantly higher Psoriatic Arthritis Response Criteria response rate than placebo (58.9 vs. 29.7%; p < 0.0001). Significant differences in favor of leflunomide were also observed in the Psoriasis Area and Severity Index (PASI 50 in 30.4% of patients vs. 18.9% for placebo; p = 0.05), target lesion response (46.4 vs. 25.3%; p = 0.0048), combined skin and joint response (27.2 vs. 8.9%; p < 0.0001), Dermatology Life Quality Index (improvement of 1.9 points vs. 0.2; p = 0.0173) and certain SF-36 subdomains. Dermatological responses were observed at the earliest examination (4 weeks) and increased throughout the 24-week study., Conclusion: Once-daily oral leflunomide is an effective and convenient treatment for PsA and plaque psoriasis., (2006 S. Karger AG, Basel)
- Published
- 2006
- Full Text
- View/download PDF
16. Measuring treatment effect on psoriatic arthritis-related domains: insights from the SPIRIT-H2H study at weeks 24 and 52
- Author
-
Behrens, Frank, Leage, Soyi Liu, Sapin, Christophe, Baou, Celine El, De La Torre, Inmaculada, Meszaros, Gabriella, Schett, Georg, Combe, Bernard, van den Bosch, Filip, and Gossec, Laure
- Published
- 2021
- Full Text
- View/download PDF
17. Etanercept in Axial Spondyloarthritis, Psoriatic Arthritis, and Plaque Psoriasis: Real-World Outcome Data from German Non-interventional Study ADEQUATE.
- Author
-
Feist, Eugen, Baraliakos, Xenofon, Behrens, Frank, Thaçi, Diamant, Plenske, Anja, Klaus, Pascal, and Meng, Thomas
- Subjects
PSORIATIC arthritis ,SPONDYLOARTHROPATHIES ,JOINT pain ,PSORIASIS ,ETANERCEPT ,RHEUMATOID arthritis - Abstract
Introduction: For chronic diseases such as axial spondyloarthritis (axSpA), psoriatic arthritis (PsA), and plaque psoriasis (PsO), treatment goals include remission or at least low disease activity (LDA) by 12 weeks. Improvements in symptoms such as pain and fatigue should also be treatment goals. Methods: ADEQUATE was a German, prospective, non-interventional study to evaluate the proportion of patients with rheumatoid arthritis, PsA, axSpA, or PsO who, in routine clinical practice, benefit from the continuation of treatment with etanercept (ETN) beyond 12 weeks, even when their treatment goals have not yet been reached. Patient-reported outcomes (PROs) and changes in concomitant glucocorticoid use were also recorded. This article focuses on results for patients with axSpA and PsA; data for patients with PsO are described briefly. Results: In total, 305, 254, and 70 patients with axSpA, PsA, and PsO, respectively, were included. Rates of remission at week 12 and week 24, respectively, were 19% and 18% for axSpA, 38% and 51% for PsA, and 7% and 19% for PsO. Rates of LDA at week 12 and week 24, respectively, were 39% and 45% for axSpA, 50% and 60% for PsA, and 34% and 51% for PsO. Extending treatment up to 52 weeks was associated with stable rates of or further increases in remission and LDA rates. Improvements in pain, fatigue, and depression (axSpA, PsA, and PsO) and reductions in concomitant glucocorticoid use (axSpA and PsA) were observed. No new safety signals were detected. Conclusion: These findings confirm the effectiveness and safety of ETN in routine clinical practice for several indications and highlight potential benefits of continuing ETN treatment in patients who have not reached their treatment goals after 12 weeks. Additional benefits included improvements in PROs and reduction of concomitant glucocorticoids. Trial Registration: ClinicalTrials.gov NCT02486302. Plain Language Summary: Axial spondyloarthritis is a disorder that causes joint pain mainly in the spine and can cause deformation of the spine. Psoriatic arthritis and plaque psoriasis are disorders that cause dry, itchy, and raised skin patches. Psoriatic arthritis also causes swollen, stiff, and painful joints. Etanercept is a treatment used to reduce the symptoms of axial spondyloarthritis, psoriatic arthritis, and plaque psoriasis. The aim of treatment is remission, or low disease activity after 12 weeks. In this study, people received etanercept for up to 52 weeks from their usual doctors in Germany. A total of 305 people with axial spondyloarthritis, 254 people with psoriatic arthritis, and 70 people with plaque psoriasis took part in the study. After 12 weeks of treatment, 19 in 100 people with axial spondyloarthritis were in remission and 39 in 100 people had low disease activity. In addition, 38 in 100 people with psoriatic arthritis were in remission and 50 in 100 people had low disease activity. Finally, 7 in 100 people with plaque psoriasis were in remission and 34 in 100 people had low disease activity. These numbers remained mostly stable until the end of the study. People also reported less pain, fatigue, and depression. Most people were able to use less glucocorticoids. The number and types of unwanted side effects were similar to those seen in other studies of etanercept in people with axial spondyloarthritis, psoriatic arthritis, or plaque psoriasis. [ABSTRACT FROM AUTHOR]
- Published
- 2024
- Full Text
- View/download PDF
18. Proceedings of the Collaborative Research Network Meeting at the GRAPPA 2022 Annual Meeting.
- Author
-
Cheok Kuan Ng, Beverly, Jadon, Deepak, Behrens, Frank, de Wit, Maarten, FitzGerald, Oliver, Gladman, Dafna D., Mease, Philip J., O'Sullivan, Denis, Pennington, Stephen R., Schett, Georg, Chandran, Vinod, and de Vlam, Kurt
- Abstract
At the Group for Research and Assessment of Psoriasis and Psoriatic Arthritis (GRAPPA) 2022 annual meeting, the Collaborative Research Network (CRN) met to present updates on several projects. These included the GRAPPA-Industry biomarker projects, Axial Psoriatic Arthritis Molecular and Clinical Characterisation Study, Axial Involvement in Psoriatic Arthritis Cohort (AXIS) study, and the Health Initiatives in Psoriasis and Psoriatic Arthritis Consortium European States (HIPPOCRATES). The meeting concluded with a discussion on pathways to further academia-industry collaboration. [ABSTRACT FROM AUTHOR]
- Published
- 2023
- Full Text
- View/download PDF
19. A Comprehensive Review of Ixekizumab Efficacy in Nail Psoriasis from Clinical Trials for Moderate-to-Severe Psoriasis and Psoriatic Arthritis.
- Author
-
Kirkham, Bruce W., Egeberg, Alexander, Behrens, Frank, Pinter, Andreas, Merola, Joseph F., Holzkämper, Thorsten, Gallo, Gaia, Ng, Khai Jing, Bolce, Rebecca, Schuster, Christopher, Nash, Peter, and Puig, Luis
- Subjects
NAIL diseases ,PSORIATIC arthritis ,PSORIASIS ,CLINICAL trials ,MONOCLONAL antibodies - Abstract
Nail psoriasis is a difficult-to-treat manifestation of psoriatic disease affecting up to 80% of patients with psoriatic arthritis (PsA) and 40–60% of patients with plaque psoriasis (PsO). Ixekizumab (IXE), a high-affinity monoclonal antibody that selectively targets interleukin-17A, is approved for the treatment of patients with PsA and patients with moderate-to-severe PsO. This narrative review aims to summarize nail psoriasis data generated from IXE clinical trials in patients with PsA (SPIRIT-P1, SPIRIT-P2, and SPIRIT-H2H) and/or moderate-to-severe PsO (UNCOVER-1, -2, -3, IXORA-R, IXORA-S, and IXORA-PEDS) with an emphasis on head-to-head clinical trial data. Across numerous trials explored, IXE treatment was associated with greater improvement in resolution of nail disease versus comparators at week 24, results which were maintained up to and beyond week 52. Additionally, patients experienced higher rates of resolution of nail disease versus comparators at week 24 and maintained high levels of resolution up to week 52 and beyond. In both PsA and PsO, IXE demonstrated efficacy in treating nail psoriasis, and therefore may be an effective therapy option. Trial Registration: ClinicalTrials.gov identifier UNCOVER-1 (NCT01474512), UNCOVER-2 (NCT01597245), UNCOVER-3 (NCT01646177), IXORA-PEDS (NCT03073200), IXORA-S (NCT02561806), IXORA-R (NCT03573323), SPIRIT-P1 (NCT01695239), SPIRIT-P2 (NCT02349295), SPIRIT-H2H (NCT03151551). [ABSTRACT FROM AUTHOR]
- Published
- 2023
- Full Text
- View/download PDF
20. POS0881 Specific AI-Generated Pattern of Tender Joints and Tenderness at Enthesial Sites are Predictive for Objective Detection of Musculoskeletal Inflammation in Psoriasis Patients
- Author
-
Köhm, Michaela, Pick, Annika, Kugler, Sabine, Mackay, Sina, Antweiler, Dario, Kratz, Hannah, Zerweck, Lukas, Rüping, Stefan, Behrens, Frank, and Publica
- Subjects
dimension reduction ,psoriasis arthritis ,psoriasis ,clustering - Abstract
Psoriasis (Pso) is one of the most common chronic inflammatory skin diseases in Europe. Psoriatic arthritis (PsA) is closely associated to Pso. Up to 30% of the Pso patients will develop PsA during skin disease course. Defined and validated approaches for early detection are still missing. Beside biomarkers from blood or imaging, clinical characteristics of the patients may be of value to detect PsA patients in the transition state early. To perform an AI-based cluster analysis in a cohort of Pso patients at-risk for development of PsA to assess clinical characteristics as markers for early PsA.
- Published
- 2023
21. Application of clinical and molecular profiling data to improve patient outcomes in psoriatic arthritis.
- Author
-
FitzGerald, Oliver, Behrens, Frank, Barton, Anne, Bertheussen, Heidi, Boutouyrie-Dumont, Bruno, Coates, Laura, Davies, Owen, de Wit, Maarten, Fagni, Filippo, Goodyear, Carl S., Gurke, Robert, Hahnefeld, Lisa, Huppertz, Christine, Ioannidis, Vassilios, Ibberson, Mark, Katz, Arnon, Klippstein, Maximilian, Koehm, Michaela, Korish, Shimon, and Mackay, Sina
- Subjects
PATIENT reported outcome measures ,PSORIATIC arthritis ,MULTIOMICS ,COOPERATIVE research ,MOLECULAR diagnosis - Abstract
Achieving a good outcome for a person with Psoriatic Arthritis (PsA) is made difficult by late diagnosis, heterogenous clinical disease expression and in many cases, failure to adequately suppress inflammatory disease features. Single-centre studies have certainly contributed to our understanding of disease pathogenesis, but to adequately address the major areas of unmet need, multi-partner, collaborative research programmes are now required. HIPPOCRATES is a 5-year, Innovative Medicines Initiative (IMI) programme which includes 17 European academic centres experienced in PsA research, 5 pharmaceutical industry partners, 3 small-/medium-sized industry partners and 2 patient-representative organizations. In this review, the ambitious programme of work to be undertaken by HIPPOCRATES is outlined and common approaches and challenges are identified. It is expected that, when completed, the results will ultimately allow for changes in the approaches to diagnosing, managing and treating PsA allowing for better short-term and long-term outcomes. Plain language summary: Improving outcomes in Psoriatic Arthritis Psoriatic Arthritis (PsA) is a form of arthritis which is found in approximately 30% of people who have the skin condition, Psoriasis. Frequently debilitating and progressive, achieving a good outcome for a person with PsA is made difficult by late diagnosis, disease clinical features and in many cases, failure to adequately control features of inflammation. Research studies from individual centres have certainly contributed to our understanding of why people develop PsA but to adequately address the major areas of unmet need, multi-centre, collaborative research programmes are now required. HIPPOCRATES is a 5-year, Innovative Medicines Initiative (IMI) programme which includes 17 European academic centres experienced in PsA research, 5 pharmaceutical industry partners, 3 small-/medium-sized industry partners and 2 patient representative organisations (see appendix). In this review, the ambitious programme of work to be undertaken by HIPPOCRATES is outlined and common approaches and challenges are identified. The participation of patient research partners in all stages of the work of HIPPOCRATES is highlighted. It is expected that, when completed, the results will ultimately allow for changes in the approaches to diagnosing, managing and treating PsA allowing for improvements in short-term and long-term outcomes. [ABSTRACT FROM AUTHOR]
- Published
- 2023
- Full Text
- View/download PDF
22. Efficacy and safety of risankizumab for active psoriatic arthritis: 24-week results from the randomised, double-blind, phase 3 KEEPsAKE 1 trial
- Author
-
Kristensen, L.E., Keiserman, M., Papp, K., McCasland, L., White, D., Lu, W., Wang, Z., Soliman, A.M., Eldred, A., Barcomb, L., Behrens, Frank, and Publica
- Subjects
Psoriatic Arthritis ,Immunology ,Antibodies, Monoclonal ,General Biochemistry, Genetics and Molecular Biology ,arthritis ,Rheumatology ,biological therapy ,Humans ,Psoriasis ,Immunology and Allergy ,psoriatic - Abstract
ObjectiveTo evaluate risankizumab, a biological therapy that inhibits interleukin 23, in patients with active psoriatic arthritis (PsA) who have responded inadequately or are intolerant to ≥1 conventional synthetic disease-modifying antirheumatic drug (csDMARD).MethodsIn the randomised, placebo-controlled, double-blind KEEPsAKE 1 trial, 964 patients with active PsA were randomised (1:1) to receive risankizumab 150 mg or placebo at weeks 0, 4 and 16. The primary endpoint was the proportion of patients achieving ≥20% improvement in American College of Rheumatology criteria (ACR20) at week 24. Here, we report the results from the 24-week double-blind period; the open-label period with all patients receiving risankizumab is ongoing.ResultsAt week 24, a significantly greater proportion of patients receiving risankizumab achieved the primary endpoint of ACR20 (57.3% vs placebo, 33.5%; pConclusionsRisankizumab treatment results in significantly greater improvement of signs and symptoms of PsA compared with placebo and is well tolerated in patients with active PsA who have responded inadequately or are intolerant to ≥1 csDMARD.Trial registration numberNCT03675308.
- Published
- 2021
23. Behandlung der Psoriasis mit Secukinumab
- Author
-
Körber, Andreas, Augustin, Matthias, Behrens, Frank, Gerdes, Sascha, von Kiedrowski, Ralph, Schäkel, Knut, Sticherling, Michael, Wilsmann-Theis, Dagmar, Wohlrab, Johannes, and Simon, Jan-Christoph
- Subjects
Infektionen ,Biologika ,Übersichten ,Antibodies, Monoclonal ,Besondere Situationen ,Comorbidity ,Special situations ,Infections ,Antibodies, Monoclonal, Humanized ,Severity of Illness Index ,Perioperatives Management ,Treatment Outcome ,Komorbidität ,Pregnancy ,Perioperative management ,Quality of Life ,Humans ,Psoriasis ,Female ,Biological products - Abstract
Moderate to severe plaque psoriasis can be treated effectively with immunomodulating biologicals such as the interleukin-17A inhibitor secukinumab. In practice, however, questions often arise as to how to proceed in special situations, such as infections, comorbidity, pregnancy, or surgery.To address frequent questions about the treatment of plaque psoriasis with secukinumab in a consensus document of German psoriasis experts that supplements current guidelines.In a virtual expert meeting in May 2020, practical aspects of the treatment of psoriasis were discussed based on the experience of the participants and on current literature. The results of this discussion were summarized in the present consensus document.This article provides practical guidance on case history, documentation of previous therapies, severity of psoriasis, and comorbidities before starting therapy with secukinumab. For patients treated with secukinumab, the course of action in case of vaccinations, chronic or acute infections, surgical interventions, special manifestations of psoriasis, and comorbidities including history of cancer and autoimmune disorders is discussed. Questions regarding family planning and health policy regulations are also addressed.The recommendations for the treatment of psoriasis with secukinumab summarized in this consensus document may contribute to achieve optimal therapy for patients and to improve their quality of life.HINTERGRUND: Die mittelschwere bis schwere Psoriasis vulgaris kann wirksam mit immunmodulierenden Biologika wie dem Interleukin-17A-Inhibitor Secukinumab behandelt werden. In der Praxis stellt sich jedoch oft die Frage nach dem Vorgehen in besonderen Situationen, beispielsweise bei Infektionen, Komorbidität, Schwangerschaft oder operativen Eingriffen.In diesem Konsensdokument deutscher Psoriasisexperten sollen in Ergänzung zu den aktuellen Leitlinien häufige Fragen aus dem Therapiealltag zur Behandlung der Psoriasis mit Secukinumab beantwortet werden.In einem virtuellen Expertentreffen im Mai 2020 wurden auf Grundlage von Erfahrungen der Teilnehmer und aktueller Literatur praxisrelevante Aspekte der Behandlung der Psoriasis erörtert. Darauf basierend wurde ein Konsensdokument verfasst.Die vorliegende Arbeit bietet praktische Hinweise zur Anamnese einschließlich der Erfassung von Vortherapien, Schweregrad der Psoriasis und Begleiterkrankungen vor Beginn einer Therapie mit Secukinumab. Ferner wird auf das Vorgehen bei Impfungen, Infektionen, operativen Eingriffen, Sondermanifestationen der Psoriasis und Komorbiditäten einschließlich vorbestehenden Autoimmunerkrankungen und Tumorerkrankungen unter Therapie mit Secukinumab eingegangen. Auch Fragen zur Familienplanung und zu gesundheitspolitischen Regularien werden diskutiert.Die in diesem Konsensdokument zusammengefassten unterstützenden Empfehlungen zur Behandlung der Psoriasis mit Secukinumab sollen dazu beitragen, für die Patienten eine optimale Therapie zu erreichen und ihre Lebensqualität zu verbessern.
- Published
- 2021
24. Omics and Multi-Omics Analysis for the Early Identification and Improved Outcome of Patients with Psoriatic Arthritis
- Author
-
Gurke, Robert, Bendes, Annika, Bowes, John, Koehm, Michaela, Twyman, Richard M., Barton, Anne, Elewaut, Dirk, Goodyear, Carl, Hahnefeld, Lisa, Hillenbrand, Rainer, Hunter, Ewan, Ibberson, Mark, Ioannidis, Vassilios, Kugler, Sabine, Lories, Rik J., Resch, Eduard, Rueping, Stefan, Scholich, Klaus, Schwenk, Jochen M., Waddington, James C., Whitfield, Phil, Geisslinger, Gerd, FitzGerald, Oliver, Behrens, Frank, Pennington, Stephen R., Consortium, HIPPOCRATES, and Publica
- Subjects
RISK ,psoriatic arthritis ,Biochemistry & Molecular Biology ,Science & Technology ,Medicine (miscellaneous) ,Biology and Life Sciences ,psoriasis ,Research & Experimental Medicine ,multi-omics ,METABOLOMICS ,DIAGNOSIS ,General Biochemistry, Genetics and Molecular Biology ,IDENTIFY POTENTIAL BIOMARKERS ,RHEUMATOID-ARTHRITIS ,SERUM ,ALPHA ,Medicine, Research & Experimental ,INFLAMMATION ,PRECISION MEDICINE ,Medicine and Health Sciences ,PROTEOMICS ,Pharmacology & Pharmacy ,Life Sciences & Biomedicine ,data integration ,psoriatic diseases - Abstract
The definitive diagnosis and early treatment of many immune-mediated inflammatory diseases (IMIDs) is hindered by variable and overlapping clinical manifestations. Psoriatic arthritis (PsA), which develops in ~30% of people with psoriasis, is a key example. This mixed-pattern IMID is apparent in entheseal and synovial musculoskeletal structures, but a definitive diagnosis often can only be made by clinical experts or when an extensive progressive disease state is apparent. As with other IMIDs, the detection of multimodal molecular biomarkers offers some hope for the early diagnosis of PsA and the initiation of effective management and treatment strategies. However, specific biomarkers are not yet available for PsA. The assessment of new markers by genomic and epigenomic profiling, or the analysis of blood and synovial fluid/tissue samples using proteomics, metabolomics and lipidomics, provides hope that complex molecular biomarker profiles could be developed to diagnose PsA. Importantly, the integration of these markers with high-throughput histology, imaging and standardized clinical assessment data provides an important opportunity to develop molecular profiles that could improve the diagnosis of PsA, predict its occurrence in cohorts of individuals with psoriasis, differentiate PsA from other IMIDs, and improve therapeutic responses. In this review, we consider the technologies that are currently deployed in the EU IMI2 project HIPPOCRATES to define biomarker profiles specific for PsA and discuss the advantages of combining multi-omics data to improve the outcome of PsA patients. ispartof: BIOMEDICINES vol:10 issue:10 ispartof: location:Switzerland status: published
- Published
- 2022
25. Innovative Imaging Technique for Visualization of Vascularization and Established Methods for Detection of Musculoskeletal Inflammation in Psoriasis Patients
- Author
-
Köhm, Michaela, Zerweck, Lukas, Ngyuen, Phuong-Ha, Burkhardt, Harald, Behrens, Frank, and Publica
- Subjects
psoriatic arthritis ,Medicine ,imaging ,ddc:610 ,Review ,psoriasis ,General Medicine ,early detection ,musculoskeletal inflammation - Abstract
Psoriasis (PsO) is one of the common chronic inflammatory skin diseases. Approximately 3% of the European Caucasian population is affected. Psoriatic arthritis (PsA) is a chronic immune-mediated disease associated with PsO characterized by distinct musculoskeletal inflammation. Due to its heterogeneous clinical manifestations (e.g., oligo- or polyarthritis, enthesitis, dactylitis, and axial inflammation), early diagnosis of PsA is often difficult and delayed. Approximately 30% of PsO patients will develop PsA. The responsible triggers for the transition from PsO only to PsA are currently unclear, and the impacts of different factors (e.g., genetic, environmental) on disease development are currently discussed. There is a high medical need, recently unmet, to specifically detect those patients with an increased risk for the development of clinically evident PsA early to initiate sufficient treatment to inhibit disease progression and avoid structural damage and loss of function or even intercept disease development. Increased neoangiogenesis and enthesial inflammation are hypothesized to be early pathological findings in PsO patients with PsA development. Different disease states describe the transition from PsO to PsA. Two of those phases are of value for early detection of PsA at-risk patients to prevent later development of PsA as changes in biomarker profiles are detectable: the subclinical phase (soluble and imaging biomarkers detectable, no clinical symptoms) and the prodromal phase (imaging biomarkers detectable, unspecific musculoskeletal symptoms such as arthralgia and fatigue). To target the unmet need for early detection of this at-risk population and to identify the subgroup of patients who will transition from PsO to PsA, imaging plays an important role in characterizing patients precisely. Imaging techniques such as ultrasound (US), magnetic resonance imaging (MRI), and computerized tomography (CT) are advanced techniques to detect sensitively inflammatory changes or changes in bone structure. With the use of these techniques, anatomic structures involved in inflammatory processes can be identified. These techniques are complemented by fluorescence optical imaging as a sensitive method for detection of changes in vascularization, especially in longitudinal measures. Moreover, high-resolution peripheral quantitative CT (HR-pQCT) and dynamic contrast-enhanced MRI (DCE-MRI) may give the advantage to identify PsA-related early characteristics in PsO patients reflecting transition phases of the disease.
- Published
- 2020
- Full Text
- View/download PDF
26. A head-to-head comparison of the efficacy and safety of ixekizumab and adalimumab in biological-naïve patients with active psoriatic arthritis: 24-week results of a randomised, open-label, blinded-assessor trial.
- Author
-
Mease, Philip J., Smolen, Josef S., Behrens, Frank, Nash, Peter, Soyi Liu Leage, Lingnan Li, Tahir, Hasan, Gooderham, Melinda, Krishnan, Eswar, Hong Liu-Seifert, Emery, Paul, Pillai, Sreekumar G., Helliwell, Philip S., Liu Leage, Soyi, Li, Lingnan, Liu-Seifert, Hong, and SPIRIT H2H study group
- Subjects
THERAPEUTIC use of monoclonal antibodies ,PSORIATIC arthritis ,PSORIASIS ,ANTIRHEUMATIC agents ,TREATMENT effectiveness ,COMPARATIVE studies ,RANDOMIZED controlled trials ,BLIND experiment ,STATISTICAL sampling - Abstract
Objectives: To compare efficacy and safety of ixekizumab (IXE) to adalimumab (ADA) in biological disease-modifying antirheumatic drug-naïve patients with both active psoriatic arthritis (PsA) and skin disease and inadequate response to conventional synthetic disease-modifying antirheumatic drug (csDMARDs).Methods: Patients with active PsA were randomised (1:1) to approved dosing of IXE or ADA in an open-label, head-to-head, blinded assessor clinical trial. The primary objective was to evaluate whether IXE was superior to ADA at week 24 for simultaneous achievement of a ≥50% improvement from baseline in the American College of Rheumatology criteria (ACR50) and a 100% improvement from baseline in the Psoriasis Area and Severity Index (PASI100). Major secondary objectives, also at week 24, were to evaluate whether IXE was: (1) non-inferior to ADA for achievement of ACR50 and (2) superior to ADA for PASI100 response. Additional PsA, skin, treat-to-target and quality-of-life outcome measures were assessed at week 24.Results: The primary efficacy endpoint was met (IXE: 36%, ADA: 28%; p=0.036). IXE was non-inferior for ACR50 response (IXE: 51%, ADA: 47%; treatment difference: 3.9%) and superior for PASI100 response (IXE: 60%, ADA: 47%; p=0.001). IXE had greater response versus ADA in additional PsA, skin, nail, treat-to-target and quality-of-life outcomes. Serious adverse events were reported in 8.5% (ADA) and 3.5% (IXE) of patients.Conclusions: IXE was superior to ADA in achievement of simultaneous improvement of joint and skin disease (ACR50 and PASI100) in patients with PsA and inadequate response to csDMARDs. Safety and tolerability for both biologicals were aligned with established safety profiles. [ABSTRACT FROM AUTHOR]- Published
- 2020
- Full Text
- View/download PDF
27. Combination of questionnaires for diagnosis of Psoriatic Arthritis and fluorescence-optical imaging technique in daily routine care: Enrichment of sensitivity for detection of subclinical signs of musculoskeletal inflammation in Psoriasis?
- Author
-
Köhm, Michaela, Rossmanith, Tanja, Langer, Hans-Eckhard, Burmester, Gerd-Rüdiger, Köhler, Benjamin, Käßer, Ulrich, Backhaus, Marina, Burkhardt, Harald Louis, and Behrens, Frank
- Subjects
ddc: 610 ,Psoriasis ,PEST ,610 Medical sciences ,Medicine ,PASE ,GEPARD ,urologic and male genital diseases ,Fluoreszenz-optische Bildgebung ,Psoriasis Arthritis - Abstract
Background: Psoriasis (Pso) is one of the most common chronic inflammatory skin diseases in Europe. Psoriatic arthritis (PsA) is closely associated to Pso and appears in up to 30% of Pso patients; the skin manifestation appears usually years before PsA. Questionnaires for detection of PsA (PASE,[for full text, please go to the a.m. URL], 44. Kongress der Deutschen Gesellschaft für Rheumatologie (DGRh); 30. Jahrestagung der Deutschen Gesellschaft für Orthopädische Rheumatologie (DGORh); 26. Jahrestagung der Gesellschaft für Kinder- und Jugendrheumatologie (GKJR)
- Published
- 2016
28. An objective automated measurement of fluorescence-signal intensities in Fluorescence-Optical Imaging technique can classify early non-response of antiTNF treatment in Psoriatic Arthritis patients - interims analysis of the XPLORE-study
- Author
-
Köhm, Michaela, Rossmanith, Tanja, Henkemeier, Ulf, Aries, Peer, Alten, Rieke H.-E., Langer, Hans-Eckhard, Burkhardt, Harald Louis, and Behrens, Frank
- Subjects
musculoskeletal diseases ,ddc: 610 ,Psoriasis ,610 Medical sciences ,Medicine ,skin and connective tissue diseases ,Fluoreszenz-optische Bildgebung ,Psoriasis Arthritis - Abstract
Background: Psoriatic arthritis (PsA) is a chronic inflammatory disorder associated with joint and musculoskeletal inflammation. After failure of NSAID and DMARD treatment, antiTNF therapy is started. In daily practice response is measured by clinical examination and calculated using composite indices[for full text, please go to the a.m. URL], 44. Kongress der Deutschen Gesellschaft für Rheumatologie (DGRh); 30. Jahrestagung der Deutschen Gesellschaft für Orthopädische Rheumatologie (DGORh); 26. Jahrestagung der Gesellschaft für Kinder- und Jugendrheumatologie (GKJR)
- Published
- 2016
29. PTPN22 is associated with susceptibility to psoriatic arthritis but not psoriasis:evidence for a further PsA-specific risk locus
- Author
-
Bowes, John, Loehr, Sabine, Budu-Aggrey, Ashley, Uebe, Steffen, Bruce, Ian N., Feletar, Marie, Marzo-Ortega, Helena, Helliwell, Philip, Ryan, Anthony W., Kane, David, Korendowych, Eleanor, Alenius, Gerd-Marie, Giardina, Emiliano, Packham, Jonathan, McManus, Ross, FitzGerald, Oliver, Brown, Matthew A., Behrens, Frank, Burkhardt, Harald, McHugh, Neil, Huffmeier, Ulrike, Ho, Pauline, Reis, Andre, Barton, Anne, and Publica
- Subjects
Male ,Genotype ,Arthritis, Psoriatic ,Protein Tyrosine Phosphatase, Non-Receptor Type 22 ,Clinical and Epidemiological Research ,urologic and male genital diseases ,Polymorphism, Single Nucleotide ,Medizinische Fakultät ,Genetic Loci ,Risk Factors ,Case-Control Studies ,Humans ,Psoriasis ,Female ,Genetic Predisposition to Disease ,ddc:610 ,Genome-Wide Association Study - Abstract
OBJECTIVES: Psoriatic arthritis (PsA) is a chronic inflammatory arthritis associated with psoriasis; it has a higher estimated genetic component than psoriasis alone, however most genetic susceptibility loci identified for PsA to date are also shared with psoriasis. Here we attempt to validate novel single nucleotide polymorphisms selected from our recent PsA Immunochip study and determine specificity to PsA.METHODS: A total of 15 single nucleotide polymorphisms were selected (PImmunochip RESULTS: We found genome-wide significant association to rs2476601, mapping to PTPN22 (p=1.49×10(-9), OR=1.32), but no evidence for association in the psoriasis cohort (p=0.34) and the effect estimates were significantly different between PsA and psoriasis (p=3.2×10(-4)). Additionally, we found genome-wide significant association to the previously reported psoriasis risk loci; NOS2 (rs4795067, p=5.27×10(-9)).CONCLUSIONS: For the first time, we report genome-wide significant association of PTPN22 (rs2476601) to PsA susceptibility, but no evidence for association to psoriasis.
- Published
- 2015
30. Safety and efficacy of ixekizumab in patients with PsA and previous inadequate response to TNF inhibitors: week 52 results from SPIRIT-P2.
- Author
-
Genovese, Mark C, Combe, Benard, Kremer, Joel M, Tsai, Tsen-Fang, Behrens, Frank, Adams, David H, Lee, Chin, Kerr, Lisa, and Nash, Peter
- Subjects
THERAPEUTIC use of monoclonal antibodies ,ANTIRHEUMATIC agents ,DRUG side effects ,INFECTION ,INTERLEUKINS ,PSORIATIC arthritis ,TUMOR necrosis factors ,RANDOMIZED controlled trials ,TREATMENT effectiveness ,DISEASE incidence ,BLIND experiment ,CHEMICAL inhibitors - Abstract
Objectives To assess the long-term safety and efficacy of ixekizumab, an IL-17A antagonist, in patients with active PsA. Methods In SPIRIT-P2 (NCT02349295), patients (n = 363) with previous inadequate response to TNF inhibitors entered the double-blind period (weeks 0–24) and received placebo or ixekizumab 80 mg every 4 weeks (IXEQ4W) or every 2 weeks (IXEQ2W) following a 160-mg starting dose at week 0. During the extension period (weeks 24–156), patients maintained their original ixekizumab dose, and placebo patients received IXEQ4W or IXEQ2W (1:1). We present the accumulated safety findings (week 24 up to 156) at the time of this analysis for patients who entered the extension period (n = 310). Exposure-adjusted incidence rates (IRs) per 100 patient years are presented. ACR responses are presented on an intent-to-treat basis using non-responder imputation up to week 52. Results From week 24 up to 156 (with 228 patient years of ixekizumab exposure), 140 [61.3 IR] and 15 (6.6 IR) patients reported infections and serious adverse events, respectively. Serious adverse events included one death and four serious infections. In all patients initially treated with IXEQ4W and IXEQ2W at week 0 (non-responder imputation), ACR20 (61 and 51%), ACR50 (42 and 33%) and ACR70 (26 and 18%) responses persisted out to week 52. Placebo patients re-randomized to ixekizumab demonstrated efficacy as measured by ACR responses at week 52. Conclusion During the extension period, the overall safety profile of ixekizumab remained consistent with that observed with the double-blind period, and clinical improvements persisted up to 1 year. [ABSTRACT FROM AUTHOR]
- Published
- 2018
- Full Text
- View/download PDF
31. PTPN22 is associated with susceptibility to psoriatic arthritis but not psoriasis: evidence for a further PsA-specific risk locus.
- Author
-
Bowes, John, Loehr, Sabine, Budu-Aggrey, Ashley, Uebe, Steffen, Bruce, Ian N, Feletar, Marie, Marzo-Ortega, Helena, Helliwell, Philip, Ryan, Anthony W, Kane, David, Korendowych, Eleanor, Alenius, Gerd-Marie, Giardina, Emiliano, Packham, Jonathan, McManus, Ross, FitzGerald, Oliver, Brown, Matthew A, Behrens, Frank, Burkhardt, Harald, and McHugh, Neil
- Subjects
DISEASE susceptibility ,ESTERASES ,GENETIC polymorphisms ,GENOMES ,META-analysis ,PSORIASIS ,PSORIATIC arthritis ,RESEARCH funding ,CASE-control method ,SEQUENCE analysis ,GENOTYPES - Abstract
Objectives: Psoriatic arthritis (PsA) is a chronic inflammatory arthritis associated with psoriasis; it has a higher estimated genetic component than psoriasis alone, however most genetic susceptibility loci identified for PsA to date are also shared with psoriasis. Here we attempt to validate novel single nucleotide polymorphisms selected from our recent PsA Immunochip study and determine specificity to PsA.Methods: A total of 15 single nucleotide polymorphisms were selected (PImmunochip <1×10(-4)) for validation genotyping in 1177 cases and 2155 controls using TaqMan. Meta-analysis of Immunochip and validation data sets consisted of 3139 PsA cases and 11 078 controls. Novel PsA susceptibility loci were compared with data from two large psoriasis studies (WTCCC2 and Immunochip) to determine PsA specificity.Results: We found genome-wide significant association to rs2476601, mapping to PTPN22 (p=1.49×10(-9), OR=1.32), but no evidence for association in the psoriasis cohort (p=0.34) and the effect estimates were significantly different between PsA and psoriasis (p=3.2×10(-4)). Additionally, we found genome-wide significant association to the previously reported psoriasis risk loci; NOS2 (rs4795067, p=5.27×10(-9)).Conclusions: For the first time, we report genome-wide significant association of PTPN22 (rs2476601) to PsA susceptibility, but no evidence for association to psoriasis. [ABSTRACT FROM AUTHOR]- Published
- 2015
- Full Text
- View/download PDF
32. Association between Skin and Joint Involvement in Patients with Psoriatic Arthritis Treated with Adalimumab: Analysis of Data from a German Non-Interventional Study.
- Author
-
Thaçi, Diamant, Behrens, Frank, Greger, Gerd, Burkhardt, Harald, Gnann, Holger, Schopf, Rudolf, and Wittig, Bianca Maria
- Abstract
Background: The association between skin and joint manifestations in patients with psoriatic arthritis (PsA) requires further characterization. Objective: We evaluated the association between severity of skin disease and joint involvement and the effectiveness and safety of adalimumab in PsA patients by baseline psoriasis severity. Methods: Descriptive statistics and regression analyses were used to evaluate data from 1,918 PsA patients starting adalimumab treatment. Subgroup analyses were conducted on patients empirically grouped by baseline target lesion score as a marker of psoriasis severity. Results: Psoriasis severity was not associated with joint manifestations at baseline or after 12 months of treatment. All subgroups showed improvements in skin and joints during therapy, and adalimumab was safe and well tolerated in all subgroups. Conclusion: The severity of skin manifestations does not correlate with the severity of joint disease in PsA patients; even patients with mild skin disease may have extensive musculoskeletal involvement. © 2015 S. Karger AG, Basel [ABSTRACT FROM AUTHOR]
- Published
- 2015
- Full Text
- View/download PDF
33. Prevalence of rheumatologist-diagnosed psoriatic arthritis in patients with psoriasis in European/North American dermatology clinics.
- Author
-
Mease, Philip J., Gladman, Dafna D., Papp, Kim A., Khraishi, Majed M., Thaçi, Diamant, Behrens, Frank, Northington, Robert, Fuiman, Joanne, Bananis, Eustratios, Boggs, Robert, and Alvarez, Daniel
- Abstract
Background: Prompt identification and treatment of psoriatic arthritis (PsA) in patients with psoriasis is critical to reducing the risk of joint damage, disability, and comorbidities. Objective: We sought to estimate PsA prevalence in patients with plaque psoriasis in 34 dermatology centers in 7 European and North American countries. Methods: Consecutive patients were evaluated by dermatologists for plaque psoriasis and subsequently by rheumatologists for PsA. PsA prevalence was estimated primarily based on rheumatologists' assessment of medical history, physical examination, and laboratory tests. Results: Of 949 patients evaluated, 285 (30%) had PsA (95% confidence interval 27-33) based on rheumatologists' assessment. PsA diagnosis changed in 1.2% of patients when diagnostic laboratory tests were added to medical history and physical examination. Of 285 patients given the diagnosis of PsA, 117 (41%) had not been previously given the diagnosis. Limitations: Bias may have been introduced by lack of standardized diagnostic criteria and unbalanced recruitment based on country populations. Conclusions: In this study, almost a third of patients with psoriasis seen in dermatology centers had PsA as determined by rheumatologists. More than a third of patients with PsA had not been previously given the diagnosis. Clinical evaluation alone is often sufficient basis for PsA diagnosis, but laboratory test results may be helpful in some patients. [Copyright &y& Elsevier]
- Published
- 2013
- Full Text
- View/download PDF
Catalog
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.